Become a Founding Member for $999 a year, locked for life

    Claim a seat
    MavenlyMavenly

    § Federal grant opportunity · PAR-27-109

    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases

    National Institutes of Health is accepting applications for Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases. The deadline is Rolling / not published and the published award range is $300K – $600K.

    Key facts

    Funder
    National Institutes of Health
    Application deadline
    Rolling / not published
    Award range
    $300K – $600K
    Eligibility
    for profit organizations other than small businesses, city or township governments, small businesses, federally recognized native american tribal governments, public and indian housing authorities, private institutions of higher education, nonprofits non higher education with 501c3, other, other native american tribal organizations, special district governments, state governments, public and state institutions of higher education, county governments, nonprofits non higher education without 501c3, independent school districts
    Geography
    United States
    Focus areas
    Health
    Opportunity number
    PAR-27-109

    Program overview

    The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Exploratory Clinical Trials Grants Program in the mission areas of NIAMS. The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases. This Exploratory Clinical Trials Grants Program is designed to facilitate the execution of short-term, interventional studies. The Program is intended to support a range of exploratory studies, from proof-of-concept/first in human to Phase I and Phase II clinical trials. Such studies must meet the NIH definition of a clinical trial and be feasible within the time and budget constraints of this NOFO. A high priority is the use of such studies to stimulate the translation of promising research developments from laboratory, preclinical, and early human testing into clinical practice. Examples of research areas of interest include, but are not limited to: Conducting early-stage clinical trials, such as but not limited to; first in human, dose-finding or escalation/tolerability/safety/efficacy studies with drugs, biologics, devices, behavioral interventions, and/or physical therapy for treatment of arthritis, musculoskeletal, or skin conditions or diseases. Clinical trials to provide data required to support a future, more robust clinical trial whose aim is to help establish the safety and efficacy or effectiveness of an intervention. Clinical trials in rare diseases where the number of potential study participants is limited. Clinical trials to determine the predictive value of a potential biomarker.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from National Institutes of Health.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before Rolling / not published, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.